EyePoint will halve workforce, end pivotal wet AMD trials early following second fail
Phase 3negativeDuravyuNegative
AI Analysis
Summary
EyePoint's Duravyu failed a second Phase 3 trial in wet AMD, prompting the company to halve its workforce, end pivotal wet AMD trials early, and begin a strategic review. The company is shifting focus to Duravyu's potential in diabetic macular edema.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Duravyu failed a second Phase 3 trial in wet AMD; company will end pivotal wet AMD trials early, halve its workforce, initiate a strategic review, and shift focus to diabetic macular edema.
Importance:9/10
Sentiment:
-0.90
Phase 3 failurewet AMDlayoffsrestructuringstrategic reviewtrial terminationdiabetic macular edemaophthalmology
Related Companies
Read the original article
Published by BioSpace on October 19, 2026 4:43 PM